Avapritinib
Acute Myeloid Leukemia With T(8;21)(Q22;Q22)
The First Affiliated Hospital of Soochow UniversitySmall moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
15 Active assets in the Acute Myeloid Leukemia With T(8;21)(Q22;Q22) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Daunorubicin National Cancer Institute (NCI) | Phase 3 | BBB |
ETOPOSIDE Alice Mims | Phase 3 | BBB |
Cytosin-Arabinosid The First Affiliated Hospital of Soochow University | Phase 3 | BBB |
Idarubicine The First Affiliated Hospital of Soochow University | Phase 2 | BBB |
Cyclophosphamide BGI, China | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Avapritinib is also rated in:
systemic mastocytosis with an associated clonal hematologic non-mast cell lineage diseaseDormant
BB
Indicative ·
64 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →